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esponsibility of InstAbstract Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer drug target.
Many recent studies have provided convincing evidences of strong correlation between elevated levels of
HIF-1 and tumor metastasis, angiogenesis, poor patient prognosis as well as tumor resistance therapy. It
was found that hypoxia (low O2 levels) is a common character in many types of solid tumors. As an
adaptive response to hypoxic stress, hypoxic tumor cells activate several survival pathways to carry out
their essential biological processes in different ways compared with normal cells. Recent advances in
cancer biology at the cellular and molecular levels highlighted the HIF-1α pathway as a crucial survival
pathway for which novel strategies of cancer therapy could be developed. However, targeting the HIF-1α
pathway has been a challenging but promising progresses have been made in the past twenty years. This7
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HIF-1α pathway for cancer therapy 379review summarizes the role and regulation of the HIF-1α in cancer, and recent therapeutic approaches
targeting this important pathway.
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hypoxic stress
Mammalian cells need to maintain proper oxygen hemostasis in order
to execute their aerobic metabolism and energy generation. In cancer,
heart diseases, or chronic obstructive pulmonary disorders, the cellular
oxygen balance is highly impaired, and cells become hypoxic (having
low oxygen (O2) levels)
1. Hypoxia is common in many types of solid
tumors, where tumor cells proliferate rapidly and form large solid
tumor masses, leading to obstruction and compression of the blood
vessels surrounding these masses. These abnormal blood vessels often
do not function properly and result in poor O2 supply to the center
tumor regions2. Tumor cells in this hypoxic region begin to adapt these
low oxygen tension conditions by activating several survival pathways.
Activation of HIF-1 transcription factor is the most recognized pathway
adopted by hypoxic cells in this harsh microenvironment (reviewed in
references1–10).
Activated HIF-1 plays a crucial role in adaptive responses of the
tumor cells to changes in oxygen through transcriptional activation of
over 100 downstream genes which regulate vital biological processes
required for tumor survival and progression. Examples include genes
involved in glucose metabolism, cell proliferation, migration and
angiogenesis11 (Fig. 1). For example, in a rapidly growing tumor
tissue, HIF-1 helps hypoxic tumor cells to shift glucose metabolism
from the more efﬁcient oxidative phosphorylation to the less efﬁcient
glycolytic pathway in order to maintain their energy production (the
Warburg effect)12. For this reason, hypoxic cells tend to consume more
glucose in order to meet their energy needs. HIF-1 mediates this
metabolic conversion through the induction of enzymes involved in the
glycolysis pathway and overexpression of glucose transporters
(GLUTs) which increase glucose import into tumor cells3. Another
example involves the HIF-1 transcriptional induction of several pro-
angiogenic factors such as the vascular endothelial growth factor
(VEGF), which in turn stimulates the development of new blood
vessels to enrich tumor cells with oxygen for their growth13. In
addition, HIF-1 promotes tumor metastasis into distant and more
oxygenated tissues through the transcriptional activation of oncogenic
growth factors such as transforming growth factor beta3 (TGF-β3),
epidermal growth factor (EGF) and others13,14. Altogether, HIF-1
activation in tumor cells is one of the key masters orchestrating their
adaptation mechanisms to the hypoxia environment.2. Discovery of the HIF-1 protein
HIF-1 was initially discovered by Semenza and co-workers15 in 1991
during a study conducted on erythropoietin (EPO) gene, a gene
responsible for encoding erythropoietin hormone for red blood cells
production. Cis-acting DNA sequences (50–RCGTG-30) were identiﬁed
in the 30-ﬂanking region of this EPO gene. These DNA sequences
were found to be essential for the transcriptional activation of EPO
gene in response to hypoxia and thus they were named as hypoxia
response elements (HRE). Further studies discovered that thetranscriptional activation of many regulatory genes is initiated through
binding of a speciﬁc protein that is induced under hypoxia conditions
to the HRE. Later this protein was identiﬁed as HIF-116.3. HIF-1 structure
HIF-1 is a heterodimeric transcription factor, composed of two
subunits, the HIF-1α (or its analogs HIF-2α and HIF-3α) and HIF-
1β subunits17. HIF-1α is an oxygen sensitive subunit and its expression
is induced under hypoxic conditions. In contrast, HIF-1β is constitu-
tively expressed. HIF-1β is also known as aryl hydrocarbon nuclear
translocator (ARNT), because it was discovered before HIF-1α and
was identiﬁed as a heterodimeric partner of aryl hydrocarbon receptor
(AhR). HIF-1β binds to AhR facilitating its translocation to the
nucleus17. These two subunits belong to bHLH-PAS protein family,
because their structures are related to two nuclear proteins found in
Drosophila (Per and Sim, PAS) which have basic-helix-loop-helix
(bHLH) motif18,19 (Fig. 2). The bHLH proteins are characterized by
having recognizable domains (b, HLH, PAS and TAD) which can
regulate their own transcriptions as well as expression of other
family members. In general, the bHLH-PAS motifs are essential to
allow heterodimer formation between HIF-1α and HIF-1β subunits and
for binding to the HRE-DNA sequence on the target genes. Base
domains were found to have DNA binding properties required for
binding the HRE on the gene, while HLH motif is where dimerization
with other proteins occurs. Interestingly, PAS was found to be the only
domain which is conserved among all members of this protein family
(HIF-1α, ARNT, AhR, and PAS) and not found in any other types of
proteins.
The HIF-1α subunit has two transactivation domains (TAD):
NH2-terminal (N-TAD) and COOH-terminal (C-TAD). These two
domains are responsible for HIF-1α transcriptional activity20. C-
TAD interacts with co-activators such as CBP/p300 to modulate
gene transcription of HIF-1α under hypoxia. N-TAD is responsible
for stabilizing HIF-1α against degradation21. Moreover, all HIF-α
subunits are distinct from HIF-1β in that they all have an oxygen-
dependent degradation domain (ODDD) overlapping N-TAD in
their structures. This ODDD domain is important in mediating O2
regulation stability22 (Fig. 2).
Three closely related isoforms of HIF-α were known: HIF-1α, HIF-
2α, and HIF-3α20,23. Unlike HIF-3α, HIF-2α shows a noticeable degree
of amino acid sequence similarity with HIF-1α (48% sequence
similarity). This identity resemblance could explain their common
capability of hetero-dimerization with HIF-1β and binding with HREs.
Interestingly, HIF-1α and HIF-2α show different pattern of tissue
distributions. HIF-1α is ubiquitously expressed in the body, but HIF-2α
expression is stricter to speciﬁc tissues23. HIF-3α was less known until
the discovery of the inhibitory PAS (IPAS), a spliced variant of HIF-
3α. This domain doesn't show any intrinsic transactivation activity in
comparison to the C-TAD of HIF-1α and HIF-2α, and it is a dominant-
negative regulator over HIF-1/DNA binding ability24.
Figure 2 Functional domains (bHLH, PAS, TAD) for proteins related to bHLH-PAS family. HIF-1α and HIF-2α share high degree of amino acid
sequence similarities and both of them have two distinct TADs (C-TAD and N-TAD). In contrast, HIF-3α only has N-TAD.
Figure 1 Representative HIF-1α regulatory genes and their effects on cancer progression. LEP, leptin; NOS, nitric oxide synthase; VEGF,
vascular endothelial growth factor; LRP1, LDL-receptor-related protein 1; ADM, adrenomedullin; TGF-β3, transforming growth factor-β3; EPO,
erythropoietin; HK1, hexokinase 1; HK2, hexokinase 2; GLUT1, glucose transporter 1; GLUT3, glucose transporter 3; LDHA, lactate
dehydrogenase; PKM, pyruvate kinase M; IGF2, insulin-like growth factor 2; IGF-BP2, IGF-factor-binding protein 2; IGF-BP3, IGF-factor-
binding protein 3; TGF-α, transforming growth factor α; C-MYC, myelocytomatosis virus oncogene cellular homolog; ID2, DNA-binding protein
inhibitor7.
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The activity and accumulation of HIF-1α protein were found to be
regulated at different levels throughout its life cycle inside the cells.
Independently from O2 levels, HIF-1α is constitutively transcribed and
synthesized through a series of signaling events involving several
growth factors and other signaling molecules25 (Fig. 3a). HIF-1α
undergoes quick degradation under normoxic conditions and normally
has a very short half-life (about 5 min)26. In contrast, under hypoxic
conditions, several pathways have been shown to control HIF-1α
stability and transcriptional activity via post-transnational modiﬁcations
involving hydroxylation, acetylation, ubiquitination, and phosphoryla-
tion reactions, as discussed below25.4.1. Oxygen-dependent regulation of HIF-1α pathway ‘hypoxic
regulation’
4.1.1. pVHL-dependent pathway
Under normal oxygen tension, HIF-1α protein expression is negatively
regulated by proteasomal degradation and ubiquitination in a pathway
involving von HippelLindau protein (pVHL), a tumor suppressor
protein and one of the recognized components of an E3 ubiquitin
protein ligase27. The two proline residues (P402/ P564) located in the
LXXLAP amino acid motif in the ODDD of HIF-1α were found to be
good substrates for the action of a group of enzymes called prolyl-4-
hydroxylases (PHDs) or HIF-1 prolyl hydroxylases (HPH)22,28. These
are 2-OG-dependent dioxygenases enzymes which require oxygen for
Figure 3 Regulation of HIF-1α pathway at different levels. (a) Growth factors related pathways; (b) pVHL related pathways; (c) FIH-1 pathway;
(d) Mdm2-p53 mediated ubiquitination and proteasomal degradation pathway; (e) Hsp90. Ras/Raf/MEK: Rat sarcoma/rapidly accelerated
ﬁbrosarcoma/MAPK/ERK kinase. These pathways regulate HIF-1α activity by regulating HIF-1α synthesis (a), HIF-1α stability (b, d, e), or HIF-
1α transactivation (e, c).
HIF-1α pathway for cancer therapy 381their hydroxylation action, in addition to other co-factors such as iron
and ascorbate. Hence, hydroxylation of proline residues by PHDs
occurs only when there is sufﬁcient amount of oxygen7,28 (Fig. 3b).
Moreover, another residue in the ODDD (lysine, K532) could be
acetylated by an enzyme called arrest-defective-1 (ARD-1), an acetyl
transferase enzyme29 (Fig. 3b). Although ARD activity does not
depend on oxygen availability, the expression of ARD is decreased
under hypoxia29. Consequently, modiﬁed HIF-1α subunits with
hydroxylated P402/P564 and acetylated K532 moieties are preferably
recognized by pVHL and are tagged for ubiquitination and proteasomal
degradation30. Since both the hydroxylation action from PHDs and
ARD-1 expression require the presence of oxygen, under hypoxic
condition, neither hydroxylation nor acetylation of HIF-1α proline and
lysine residues occurs, resulting in stabilization of HIF-1α structure.4.1.2. pVHL-independent pathway
Another oxygen-dependent major mechanism for negative regulation
of HIF-1α pathway under normoxia is through controlling HIF-1α
transactivation. This pathway represents another level of post-
translational modiﬁcations of HIF-1α transactivation domain but does
not involve the pVHL protein. The transcriptional activation of HIF-1α
target genes is initiated through the cooperative binding of C-TAD in
the HIF-1α and the co-activator CBP/p300. In normoxia, oxygen
dependent hydroxylation of HIF-1α asparagine (N803) residue by factor
inhibiting HIF-1 (FIH-1), also known as asparginyl hydroxylase,
blocks the interaction between the two domains, abrogating the
subsequent HIF-1α mediated gene transcription31–34 (Fig. 3c).Alternatively, hypoxia encourages this interaction through the inhibi-
tion of oxygen dependent hydroxylation of N803, resulting in
transcriptional activation of the target genes32–34.
In summary, oxygen-dependent regulation of HIF-1α pathway
involves a series of post-translational modiﬁcations. The pathway
involving pVHL regulates HIF-1α stabilization, while that not
involving VHL regulates HIF-1α transactivation.
4.2. Oxygen-independent oncogenic regulation of HIF-1α
pathway
In addition to the major role of hydroxylases in regulating HIF-1α
activity, there are pathways involving oncogenic activation that have
considerable contributions in controlling HIF-1α protein levels. In non-
hypoxic conditions, growth factors, cytokines and other signaling
molecules tend to accumulate HIF-1α protein in cells.
4.2.1. Growth factor signaling pathways
Activation of phosphatidyl inositol-4,5-bisphosphate-3-kinase (PI3K)
can upregulate the HIF-1α protein translation35–37. PI3K regulates
protein syntheses through its target protein kinase B (Akt) and
downstream component mammalian target of rapamycin (mTOR).
mTOR mediates its action via phosphorylation of the eukaryotic
translation initiation factor 4E (eIF-4E) binding protein (4E-BP1)
disrupting the integrity of these two components, which is essential
for inhibiting cap-dependent mRNA translation, resulting in enhanced
HIF-1α protein translation38 (Fig. 3a). Additionally, phosphorylation of
Figure 4 Schematic illustration of approaches adopted for discovery of HIF-1α inhibitors and investigation of their underlying inhibitory
mechanisms of action (MOAs).
Georgina N. Masoud, Wei Li382p70 S6 kinase (S6K) by mTOR promotes the phosphorylation of its
substrate, the ribosomal protein S6, and induces protein translation38
(Fig. 3a). This pathway is antagonized by the tumor suppressor protein
(PTEN) which reverses the phosphorylation of PI3K products38.
Certain growth factors activate RAS which in turn stimulates
RAS/RAF/MEK/ERK kinase cascade36 (Fig. 3a). Activated ERK
phosphorylates 4E-BP1, S6K, and MAP kinase interacting kinase
(MNK). MNK can also phosphorylate eIF-4E directly39. The net
result of these signaling events is the increased rate of mRNA
translation into HIF-1α protein. Interestingly, ERK is not only
involved in regulation of HIF-1α synthesis but also its transcrip-
tional activation. ERK phosphorylates the co-activator CBP/p300
so it increases HIF-1α/p300 complex formation, and thus stimulats
its transcriptional activation function39 (Fig. 3c).
4.2.2. Mdm2 pathway
It was observed that loss of p53 tumor suppressor gene in certain types
of tumors is associated with elevated levels of HIF-1α40. This could be
explained that in normoxia conditions, HIF-1α binds to the p53 and
allows Mdm2 (mouse double minute 2 homolog) mediated ubiquitina-
tion and proteasomal degradation of HIF-1α41 (Fig. 3d). In hypoxic
tumors, loss or mutations in tumor suppressor genes revokes any
chances for Mdm2-mediated degradation of HIF-1α.
4.2.3. Heat shock protein 90 (Hsp90)
It was reported that inhibitors of Hsp90 such as geldanamycin
(GA) could nullify HIF-1α levels regardless of the availability of
oxygen42. Hsp90 is known to bind directly with HIF-1α inducing
some conformational changes in its structure to ﬁt and couple with
HIF-1β initiating its transactivation43 (Fig. 3e). In addition, Hsp90
can stabilize HIF-1α against its non-VHL dependent degradation.5. Targeting HIF-1α pathway for cancer therapy
Considering the multiple roles of HIF-1 in tumor progression and
metastasis, there have been great interests in developing inhibitors
targeting this pathway. It is clear that HIF-1α regulation pathwayis a highly complex network involving several signaling cascades
and overlapping mechanisms, each of which could serve as a
promising target or step to intervene selectively. It is not surprising
that most of the reported HIF-1α inhibitors were originally
discovered for targeting other endogenous molecules and later
their HIF-1α inhibitory activity was recognized through some
empirical testing. For this reason, there are no speciﬁc HIF-1α
inhibitors currently and developing speciﬁc HIF-1α inhibitors in
hypoxic tumors represent a challenge.
The searching process for novel HIF-1α inhibitors usually starts
with chemical libraries screening as a preliminary step to identify
novel molecules convenient for HIF-1α inhibition testing. Follow-
ing this step, cell-based high throughput screens (HTS) are
employed to test the identiﬁed compounds for their HIF-1α
inhibitory action44. Cell-based HTS depends on measuring the
level of HIF-1α induced in mammalian cells in response to
hypoxia conditions (1% O2) or hypoxia activators, such as
deferoxamine (DFO) and cobalt chloride (CoCl2). Stably trans-
fected mammalian cell lines with constructs containing multiple
copies of HRE that drives transcription of a reporter gene
(luciferase (Luc) reporter gene is the most commonly used one)
have been widely used for testing HIF-1α inhibition. HIF-1α
inhibition can usually be achieved through modulation of one of
the following steps: HIF-1α mRNA expression; HIF-1α protein
level (protein translation or degradation); HIF-1α/HIF-1β dimer-
ization; HIF-1α-DNA binding (HIF-1α/HRE); or HIF-1α transcrip-
tional activity (CH-1 of p300/ C-TAD of HIF-1α).
To deﬁne which level within HIF-1α pathway is targeted by the
identiﬁed hit in HTS, Melillo44 described a simple algorithm for
validation purposes. This algorithm involves several consequential
steps of either cell-based or cell-free assays to consider certain level
while ruling out others involved in HIF-1α regulation to precisely
dissect the mechanism of action of the tested inhibitor44 (Fig. 4).
The ﬁrst step of this validation scheme is to test the effect of the
HIF-1α inhibitor on the hypoxic induction of mRNA expression of
HIF-1 target genes, such as VEGF, GLUT1, or EPO by reverse
transcription polymerase chain reaction (RT-PCR) or enzyme-
linked immunosorbent assay (ELISA) method45. If the tested
Figure 5 HIF-1α inhibitors modulate different levels of the HIF-1α activation pathway.
Figure 6 Chemical structures of molecules inhibiting HIF-1α pathway. Topotecan (3a): R1¼OH, R2¼CH2N(CH3)2, R3¼H, R4¼H; EZN-2208
(3b): R1¼OH, R2¼H, R3¼CH2-CH3, R4¼CO¼CH2NHCOCH2O-(40k 4-arm-PEG); SN38 (3c): R1¼ OH, R2¼ H, R3¼ CH2CH3, R4¼H;
Everolimus (4a): R1¼CH2CH2OH; Sirolimus (4b): R¼OCH3; 2ME2 (8a): R1¼OH, single bond, R2¼OH; ENDM-1198 (8b): R1¼CONH2,
double bond, R2¼H; ENMD-1200 (8c): R1¼CONH2, single bond, R2¼¼CH2; ENMD-1237 (8d): R1¼CONH2, single bond, R2¼H; GA (9a):
R¼OCH3; 17-AAG (9b): R¼–CH2NHCH2CH¼CH2; 17AG (9c): R¼NH2; 17-DMAG (9d): R¼–CH2NH(CH2)2N(CH3)2.
HIF-1α pathway for cancer therapy 383inhibitor showed negative induction effect on the target gene,
Western blotting should be the following step to measure the HIF-
1α protein levels in tumor cells cultured under hypoxia or in the
presence of hypoxia mimics (DFO, CoCl2)
46. In case the testedcompound impaired the hypoxic induction of HIF-1α protein, the
expected mechanism of action would be either hindering HIF-1α
protein translation or increasing its degradation. To specify the
involvement of protein translation or degradation, experiments can
Georgina N. Masoud, Wei Li384be conducted in the presence of proteasomal inhibitors, such as
PS-341 or MG-13247. In addition, pulse-chain experiments are
employed for assessment of de novo HIF-1α protein synthesis. The
effect of the tested compound on HIF-1α mRNA expression
should be excluded by evaluating its level48. If an inhibitor does
not negate hypoxic induction of HIF-1α protein, the other
mechanisms (DNA binding, protein dimerization, or transcrip-
tional activity) should be considered for further investigation.
ELISA, electrophoretic mobility shift assay (EMSA) and chroma-
tin immunoprecipitation (ChIP experiments) are used to test for the
inhibition of HIF-1/DNA binding49. Immunoprecipitation experi-
ments are commonly conducted to detect the inhibition of HIF-1α/
HIF-1β dimerization50. Unequivocally, the ﬁnal step in this
algorithm would be testing the inhibition of HIF-1α transcriptional
activity through testing the interaction between the CH-1 domain
of p300 and the C-TAD of HIF-1α peptides in a cell-free binding
assay51. Fig. 4 illustrates these steps.6. Molecules intervening the HIF-1α pathway
There are many small molecules reported as HIF-1α inhibitors in
literature. We categorize them in this review based on their targets,
structures and putative mechanisms of action (Figs. 5–7 and
Table 1).
6.1. Inhibitors of HIF-1α mRNA expression
EZN-2698 (1) is an anti-sense oligonucleotide, an RNA antagonist
which speciﬁcally binds and inhibits the expression of HIF-1α
mRNA as well as HIF-1α target genes. It was reported that
inhibition of HIF-1α by EZN-2698 attenuates HIF-1α protein level
and tumor progression in various in vitro (human prostate and
glioblastoma cell lines) and in vivo studies52. Phase I clinical trials
revealed that EZN-2698 is a potential agent in patients with
advanced renal cell carcinoma (RCC).
Aminoﬂavone (AF) (2) is another agent that inhibits HIF-1α
mRNA expression. Although it is known as an AhR ligand, its
exact mechanism of action as an inhibitor of HIF-1α mRNA
expression is still unclear53.
6.2. Inhibitors of HIF-1α translation
Although the nature of the regulating HIF-1α protein translation is
still poorly understood, several agents have been progressed that
target the rate of HIF-1α protein synthesis, including but not
limited to inhibitors of topoisomerase I and II, receptor tyrosine
kinase, cyclin-dependent kinase, oncogenic pathways, and micro-
tubule disrupting agents. However, the selectivity of these agents
and the contribution of HIF-1α inhibition to their activities have
not been fully established.
Camptothecins (CPTs, 3) analogues, which have topoisomerase
I (Top I) inhibitory activity, can inhibit HIF-1α protein accumula-
tion in hypoxic U251 human glioma cells. CPTs poison Top 1 by
inducing the formation of stable Top 1-DNA cleavage complexes
generating double strands DNA breaks48. Among the CPTs is
topotecan (Hycamtins–TPT, 3a) which was originally discovered
at the national cancer institute (NCI) in an HTS using a cell-based
assay of HIF-1 transcriptional activity45. Though TPT proved to be
effective as antitumor agent in xenograft models54, its short half-
life motivated the synthesis of other analogues with more favor-
able pharmacokinetic proﬁles. EZN-2208 (3b) is a TPT- congener,its high lipid solubility as a PEGylated analog of SN38 (3c), the
active metabolite of irinotecan (Camptosars–CPT-11, 3d)55, have
improved its pharmacokinetic and antitumor properties in pre-
clinical models of solid tumors and lymphomas56. A few phase I
and II clinical trials have been conducted to provide evidence as
for the anticancer activity of this agent.
mTOR Inhibitors (4) can also inhibit HIF-1α translation. The
growth factor signaling pathway involving the downstream kinases
PI3K/Akt/mTOR represents a major route of HIF-1α translation in
over 70% of human cancer cell lines8. Temsirolimus (Torisels–
CCI-779, 4), and its counterparts, everolimus or rad001 (Aﬁni-
tors, 4a) and sirolimus (Rapamycins, 4b) are mTOR inhibitors
currently in clinical development for the treatment of solid
tumors57. Although mTOR and the overall process of HIF-1α
protein synthesis are limited under normoxia, it was found that
75% of sporadic clear cell RCCs are VHL-deﬁcient, thus, in this
case HIF-1α translation can proceed smoothly serving as a target
for mTOR inhibitors intervention58. Temsirolimus and everolimus
have passed phase III clinical trials and FDA approval successfully
for treatment of metastatic RRC59. Besides being mTOR inhibitor,
temsirolimus was investigated in clinical development for treat-
ment of breast cancer owing to its antiangiogenic activity60.
Among all inhibitors of the PI3K/AKT/mTOR pathway, only
temsirolimus have gained such success.
PI3K inhibitors LY294002 (5) and wortmannin (6) have been
recognized for their anti-HIF activity. High levels of PI3K have
been recognized as a common feature of solid tumors, and it is up-
regulated by either a gain of function in PI3K itself or in its
downstream target Akt. As PI3K-speciﬁc inhibitors, LY294002 (5)
and wortmannin (6) limited the synthesis of HIF-1α protein in the
prostate carcinoma-derived cell lines PC-3 and DU145 in a dose-
dependent fashion35.
Cardiac glycosides (7) [digoxin (7a), Ouabain (7b), and
proscillaridin (7c)] have been used for the treatment of congestive
heart failure for decades. Interestingly, these drugs were identiﬁed
as inhibitors of HIF-1α protein translation and HIF-2α mRNA
expression in a cell-based screen of a library of drugs in clinical
trials. Digoxin, which is currently passing phase I clinical trials,
was reported to inhibit established tumor xenografts with no effect
on the growth of constitutively expressing HIF-1 xenografts.
These ﬁndings imply the involvement of the HIF-1 in the
antitumor activity of digoxin60.
2-Methoxyestradiol (2ME2, 8a), the natural metabolite and its
synthetic analogues [ENMD-1198 (8b), ENMD-1200 (8c), and
ENMD-1237 (8d)] have been recently recognized as antitumor and
antiangiogenic agents in several clinical trials. Mechanistically,
these agents bind to the colchicine binding site of tubulin and
disrupt tumor interphase microtubules (MTs) which are required
for HIF-1α down-regulation. It is worth mentioning that all of
these compounds have shown favorable oral bioavailability,
metabolic stability and safety proﬁles61,62. The promising clinical
beneﬁts of cancer treatment with this line of agents will no doubt
spur in research to more improved anti-tubulin drugs.6.3. Inhibitors of HIF-1α stabilization
6.3.1. Hsp90 inhibitors
The binding of HSP90 to HIF-1α promotes HIF-1α activity in two
ways: (1) it blocks the VHL-independent proteasomal degradation;
and (2) it helps HIF-1α heterodimers acquire the appropriate
conformation to recruit p300 and consequently initiate HIF-1
Figure 7 Chemical structures of molecules inhibiting HIF-1α pathway. Doxorubicin (18a): R¼CH2OH; Danuorubicin (18b): R¼CH3.
HIF-1α pathway for cancer therapy 385transactivation63. Therefore, Hsp90 antagonists are expected to
induce HIF-1α degradation.
Geldanamycins (GAs, 9) are Hsp90 inhibitors. The natural
benzoquinone ansamycin antibiotic “geldanamycin” (9a) was the ﬁrst
discovered Hsp90 inhibitor. It disrupts Hsp90 binding to client proteins
by competing with its ATP binding site, exposing them to ubi-
quitination and proteasomal degradation. Geldanamycin semi-synthetic
derivatives, 17-demethoxygeldanamycin (17-AAG, 9b) or tanespimy-
cin, 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-
DMAG, 9c) or alvespimycin hydrochloride, IPI-504 or retaspimycin,
and 17-AG (IPI-493, 9d), the major metabolite of 17-AAG and IPI-
504, have progressed successfully through clinical trials for further
clinical development by different pharmaceuticals64. However, speci-
ﬁcity of the antitumor activities of this group of agents should be
addressed, given the fact that wide range of client proteins, not only
HIF-1α may be affected by Hsp90 inhibition.
Radicicols (10) are another chemical class of Hsp90 inhibitors
possessing different and overlapping mechanisms for HIF-1α inhibi-
tion. For example, radicicol (10a) prevents the interaction between
HIF-1α/HIF-1β heterodimers and DNA attenuating the HIF-1 activa-
tion process without signiﬁcant change in HIF-1α protein stability63.
KF58333 (10b) down-regulates the HIF-1α and VEGF post-
transcriptional expression in different human cancers65.
SCH66336 (11), a farnesyltransferase derivative demonstrating
antitumor activity against non-small-cell lung cancer, inhibits the
interaction between HIF-1α and Hsp90 promoting HIF-1α protea-
somal degradation66.Apigenin (12) is an antiangiogenic natural ﬂavone. It was
reported to block hypoxia-induced up-regulation of HIF-1α,
GLUT-1, and VEGF proteins via degradation of HIF-1α through
interference with the function of Hsp9067,68.6.3.2. Histone deacetylase (HDAC) inhibitors
Recent evidence indicates that HIF-1α acetylation by p300/CBP
associated factor (PCAF) at K674 in an environment of low
NADþ is critical for promoting p300 recruitment and subse-
quent expression of HIF-1α target genes. Sirtuin 1 (SIRT 1), a
redox-sensing deacetylase considered as class III histone
deacetylase (HDAC), opposes this reaction by catalyzing HIF-
1α deacetylation at high NADþ levels. However, when hypoxia
is induced, the NADþ/NADH levels increase due to glycolysis
down-regulating SIRT-1 favoring HIF-1α activation69. The
exact mechanism of HDAC inhibitors as HIF-1α inhibitors is
still unclear, but they are known to antagonize the HIF-1α
transactivation while upregulating ubiquitin-independent degra-
dation pathways.
Romidepsin (13) and trichostatin (14) are known HDAC
inhibitors. Romidepsin (Istodaxs–FK228-FR901228, 13) is an
anticancer agent isolated from the bacterium Chromobacterium
violaceum that was ﬁrst reported by Fujisawa Pharmaceutical
Company (now Astellas Pharma) in 199470. Romidepsin is a
prodrug with disulphide bond which undergoes reduction in cells
by cellular reducing activity involving glutathione releasing a zinc-
Table 1 Classiﬁcation of molecules intervening HIF-1α pathway according to their putative mechanisms of action.
Mechanism of inhibition Inhibitor Target
HIF-1α mRNA
expression
EZN-2698 (1) HIF-1α mRNA
Aminoﬂavone (2)
HIF-1α translation CPTs (3): Topoisomerase I
topotecan (3a), EZN-2208 (3b), SN38 (3c), irinotecan (3d)
Temsirolimus (4) mTOR
Everolimus (4a)
Sirolimus (4b)
LY294002 (5) PI3K
Wortmannin (6)
Cardiac glycosides (7): HIF-1α protein/HIF-2α mRNA
digoxin (7a), ouabain (7b), proscillaridin (7c)
2ME2’s (8): Microtubules
2ME2 (8a), ENDM-1198 (8b), ENMD-1200 (8c), ENMD-1237 (8d)
HIF-1α stabilization GAs (9): Radicicol (10a),
KF58333 (10b)
SCH66336 (11),
Apigenin (12)
Hsp90
GA (9a),
17-AAG (9b),
17AG (9c),
17-DMAG (9d)
Romidepsin (KF228) (13) HDAC
Trichostatin (14)
LW6 (15) HDAC/VHL
HIF-1α dimerization Acriﬂavin (16) PAS-B
HIF-1/DNA binding Echinomycin (17) 50-CGTG-30
Anthracyclines (18): doxorubicin(18a), danuorubicin(18b) HRE
HIF-1 transcriptional
activity
Chetomin (19) CH1 domain of p300
Bortezomib (20) C-TAD of HIF-1α and Asn803 of FIH
HIF-1α at multiple levels YC-1 (21) HIF-1&2 protein/FIH
PX-478 (22) HIF-1&2 protein
Georgina N. Masoud, Wei Li386binding thiol. This thiol blocks class I HDACs activity through
reversible interaction with a zinc atom in the binding pocket of Zn-
dependent histone deacetylases. The glutathione-mediated activa-
tion also implicates its clinical usefulness for counteracting
glutathione-mediated drug resistance in chemotherapy71. Romi-
depsin along with trichostatin (14), an antifungal antibiotic, are
antiangiogenic HDAC inhibitors currently evaluated in clinical
trials against a number of solid tumors72.
LW6 (15) decreases HIF-1α protein expression through poten-
tiating VHL expression, which in turn interacts with prolyl-
hydroxylated HIF-1α for proteasomal degradation. This is demon-
strated by its antitumor activity in mice xenografts of human colon
cancer HCT116 cells. LW6 is thought to upregulate VHL
expression via different proposed mechanisms including demethy-
lation of the VHL promoter, inhibition of HDAC, or suppression
of VHL proteasomal degradation73.6.4. Inhibitors of HIF-1 dimerization
Acriﬂavin (16) is a mixture of 3,6-diamino-10-methylacridinium
chloride (trypaﬂavin) and 3,6-diaminoacridine (proﬂavine),
which was recently identiﬁed as HIF-1α inhibitor in cell-
based screening assays. Acriﬂavin inhibits HIF-1 dimerization
by binding to the PAS-B subdomain of HIF-1α and HIF-2α. Its
promising safety proﬁle and characteristic ability of binding to
both HIF-1α and HIF-2α subunits might distinguish it as a
candidate for clinical evaluation especially in cancer subtypes
where increased levels of HIF-1α and HIF-2α are the main
cause of tumor progress74.6.5. Inhibitors of HIF-1/DNA binding
Echinomycin (quinomycin A-NSC 526417, 17), a natural cyclic
peptide belonging to quinoxaline antibiotic family, was previously
identiﬁed in a HIF-1-targeted cell-based HTS at the NCI using
140,000 small-molecule library. It binds speciﬁcally to the core of
the HIF-1 recognition sequence 50–CGTG-30 in a sequence-
dependent fashion precluding HIF-1 and DNA binding. Although
immunoprecipitation experiments proved its ability to selectively
inhibit HIF-1/DNA binding, the cytotoxicity encountered during
several phase I and II clinical trials limited further clinical
evaluation of this agent49.
Anthracyclines (18), the potent well-known chemotherapeutic
agents, also act as HIF-1α inhibitors. To determine the molecular
basis for their HIF-1 inhibitory action, several mechanistic studies
were conducted and demonstrated that anthracyclines; doxorubicin
(DXR, 18a), danurubicin (DNR, 18b), epirubicin (EPI), and
idarubicin (IDA) disrupt the binding of HIF-1 to DNA in hypoxic
human cells. This is attributed to their ability to intercalate DNA
and induce topoisomerase II-mediated strand breaks75. Moreover,
administration of DXR or DNR to mice bearing human prostate
cancer xenografts signiﬁcantly inhibited tumor growth and vascu-
larization, along with a decrease of circulating angiogenic cells
(CAC). These ﬁndings imply that anthracyclines inhibition of HIF-
1 activity reduced the expression of target genes (e.g., VEGF)
responsible for tumor vascularization and growth. For this reason,
these two agents attracted considerable interest for further pre-
clinical studies to challenge the current paradigm available for
treatment of prostate cancer which is characterized by elevated
levels of HIF-1 protein76.
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Interruption of HIF-1α and HIF-1β binding to the co-factor p300
to form an active transcription complex, the ﬁnal step towards
HIF-1 transactivation, represents a potential mechanism by which
small molecules may inhibit HIF-1 activity.
Chetomin (19), the antimicrobial dithioketopiperazine fungal
metabolite, was identiﬁed as a small molecule blocking the
transcriptional co-activation of HIF-1 pathway in 2004. Chetomin
binds to and disrupts the tertiary structure of the CH1 domain of
the co-activator p300, which hinders its interaction with HIF-1 and
results in diminished HIF-1 transactivation51. While local toxicity
of chetomin restricted its further development, an interesting study
was carried out and demonstrated that chetomin HIF-1 inhibition
attenuates the expression of HIF-1 target genes and enhances the
radiotherapy efﬁcacy in human HT 1080 cells77. Chetomin is one
of many compounds indirectly affecting HIF-1α activity that
showed great promise but has failed to exhibit safety in preclinical
models.
Bortezomib (Velcades–PS-341, 20), a proteasome inhibitor,
inhibits p300-HIF-1α binding at nanomolar concentrations. Para-
doxically, at higher concentrations, it increases the level of HIF-1α
protein by blocking its proteasomal degradation. At the molecular
level, bortezomib stimulates the interaction between C-TAD of
HIF-1 and FIH target site (Asn803); thereby enhancing FIH-
mediated repression of p300 recruitment. Bortezomib is FDA
approved for the treatment of relapsed and refractory multiple
myeloma more than 10 years ago78. More recently, the ability of
bortezomib to downregulate the PI3K/AKT/mTOR pathway which
is upstream of the HIF-1 pathway was demonstrated in prostate
cancer cells79. Based on this discovery, recent studies were
designed to assess the anticancer spectrum of bortezomib as sole
agent or adjuvant therapy for the treatment of different types of
cancers80–82.6.7. Inhibitors of HIF-1α at multiple levels
YC-1 (21) is an antiplatelet aggregation agent. It was origin-
ally discovered as an activator of platelet guanylate cyclase83
and later it was found to have HIF-1 inhibitory activity. YC-1
can enhance FIH binding to HIF-α CAD, which in turn
dissociates the binding of the later to p300 co-activator and
lead to the functional repression of HIF-1. This mechanism
does not involve the FIH active site, Asn80384. YC-1 can also
impair HIF-1α and HIF-2α protein accumulation in a dose-
dependent manner85. In addition, YC-1 inhibited HIF-1α via
the FIH-dependent CAD inactivation as well as via the protein
down-regulation in HT1080 and H1299 cancer cell lines84.
Literature also revealed the anti-proliferative effect of YC-1
on cancer cells by arresting the cell cycle and promoting cell
apoptosis86.
PX-478 (22) is a melphalan derivative which has potent
antitumor activity. It was suggested that PX-478 lowers HIF-1α
levels by affecting multiple levels in the HIF-1α pathway:
(1) inhibition of HIF-1α deubiquitination via p53 and pVHL
independent mechanism, resulting in increased levels of poly-
ubiquitinated HIF-1α; (2) reduction of HIF-1α mRNA expres-
sion; and (3) inhibition of HIF-1α translation. In this regard,
PX-478 was reported active in a panel of cell lines with
prominent selectivity towards inhibition of HIF-1α protein
translation87.7. Conclusions
Hypoxia is a prominent micro-environmental feature in many
types of solid tumors due to inadequate vascularization. It accounts
for developing both radiotherapy and chemotherapy resistance.
Tumor cells respond to changes in oxygen via delegating the
transcriptional factor HIF-1α for orchestrating vast number of its
essential cellular functions. Considering the profound impacts of
HIF-1α on cancer progression via gene expression and the
unsatisfactory efﬁcacy of chemotherapy, there has been enormous
growing interest in the biology of HIF-1α pathway and the
development of direct or indirect HIF-1 inhibitors. The identiﬁca-
tion of novel HIF-1 inhibitors involves panels of cell-based or cell-
free screens and assays, but the complexity involved in the
regulation of the HIF-1α pathway has made the process of rational
design of HIF-1α inhibitors very challenging. To date, no selective
HIF-1α inhibitor has been clinically approved, partially due to the
requirements of targeting protein-protein interactions without
affecting other pathways. Nevertheless, there have been several
approved drugs that indirectly affect the HIF-1α pathway and
could serve as adjuvant therapy for certain types of cancers along
with the existing treatments. Future directions would be directed
towards developing drugs that are more speciﬁc for HIF-1
inhibition by better understanding of the molecular structure of
domains that mediate critical functions of HIF-1. With the rapid
advancement of molecular biology and emerging strategies in
efﬁciently disrupting protein-protein interactions, it is very pro-
mising that selective HIF-1 inhibitors can be developed in the
future.
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